LATTICE MEDICAL raises €43 million to transform post-cancer reconstruction
Lille, France, October 23, 2025 – LATTICE MEDICAL, a French Medtech company specializing in tissue engineering, announces a Series B fundraising round of €43 million, one of the largest of the year in the French Medtech sector. This major milestone will enable the company to accelerate the clinical development of its MATTISSE medical device, a breakthrough innovation in post-cancer breast reconstruction. This is a strong signal during Pink October, which marks LATTICE MEDICAL’s commitment to supporting women suffering from breast cancer. According to the WHO, there are 2 million new cases of breast cancer worldwide each year, and only 30% of women who have undergone a mastectomy opt for reconstruction. MATTISSE responds to a growing need for more natural, simplified breast reconstruction that does not involve foreign implants in the long term.
This significant fundraising will also enable the development of an innovative industrial tool based in Lille, which will enable the development of the local medical device industry through the integration of 3D printing technologies and resorbable biomaterials in clean rooms. It will enable LATTICE MEDICAL to position itself as a leader in the soft tissue reconstruction market. Thanks to this industrial tool, the company will develop a unique tissue engineering implant manufacturing platform to extend its technology to other therapeutic areas.
